UPDATE: Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections
June 23, 2015 at 09:08 AM EDT
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative ...
